|
|
|
|
| Advertisement |
 |
|
| COVID-19 |
|
|
| Advertisement |
Expedite Regulated Documents in the Era of COVID-19: From Development to Trials and Manufacturing
Wednesday, July 15, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
View more
|
| COVID-19 |
 |
|
|
| |
| Advertisement |
Innovation and Perseverance: Bringing a New Delivery Method to Market
The road to development for a unique formulation of an oral testosterone replacement therapy was a long one. Robert E. Dudley, PhD, Chairman, Chief Executive Officer and President at Clarus Therapeutics, Inc. talks about what this process was like and the hurdles the company faced launching amid the COVID-19 pandemic.
Access the Podcast and Q&A
|
| Q&A |
 |
|
From Fortune 500 to Startup |
Michael Wong speaks to Wayne Yetter (founding CEO of AstraMerck) and Renold (Ren) Capocasale, CEO of FlowMetric Life Sciences, about making the transition from a Fortune 500 firm to a startup
… /Read more/ |
|
|
| Pricing |
 |
|
Going Beyond Lip Service on Value |
Providing evidence for a strong value proposition to each of the access journey decision makers needs to be weighed against the risk of clinical trial failure, cost of investment, and launch timing. Ed Schoonveld outlines how a pharma company can analyze and rejuvenate its decision process
… /Read more/ |
|
| Video |
 |
|
|
|
|
|
|
| |
| Industry update |
| //Galecto (Boston, MA, and Copenhagen, Denmark), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that its Board of Directors appointed Amit Munshi as its new Chairman. The company also announced the appointment of David Shapiro, MD, the former Chief Medical Officer of Intercept Pharmaceuticals, to its Board of Directors.
|
|
|
|
|
|
|
|
|
